|
Dr. Blaschke has served on the faculty of Stanford University for over 30 years and is Professor of Medicine and Molecular Pharmacology (Active Emeritus) at the Stanford University School of Medicine. During the course of his career Dr. Blaschke has served as an independent consultant working with a number of leading pharmaceutical and biotechnology companies. Dr. Blaschke was formerly a Board member of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals two publicly-traded companies that successfully developed products (including CONCERTA® DITROPAN XL® and Viadur®) that played a substantial role in ALZA's maturation into a specialty pharmaceutical company prior to its acquisition by Johnson & Johnson. He has also worked as a special government employee for the U.S. Food and Drug Administration ("FDA") and has served as the chairman of the FDA's Generic Drugs Advisory Committee. | 